ClinicalTrials.gg
RecruitingNCT07277257Updated Dec 22, 2025

Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome

A Phase 4 interventional study of TRYPTYR (Acoltremon ophthalmic solution 0.003%) in Sjogren Syndrome With Keratoconjunctivitis, sponsored by Center For Sight. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Center For Sight · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Keratoconjunctivitis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Keratoconjunctivitis · United States.

Planned enrollment
8th of 12
35 · median 41
Started
2025
the only one that year
Phase 4
3 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Center For Sight

Among the 14 studies in Keratoconjunctivitis with a site in United States, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 4, and was the 13th registered.

Keratoconjunctivitis

27 studies on the registry are indexed under Keratoconjunctivitis; 3 are open to participants now.

Browse Keratoconjunctivitis studies →

Open to participants now

2 of the 14 studies in Keratoconjunctivitis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Keratoconjunctivitis studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Keratoconjunctivitis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.

03

Conditions studied

  • Sjogren Syndrome With Keratoconjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must fulfill the following conditions to qualify for enrollment into the trial

  1. Adults over 18 years old with a diagnosis of dry eye disease (DED) secondary to Sjögren's Syndrome within the past 2 years.
  2. History of using or desiring artificial tears for DED symptoms within the past 2 months.
  3. Unanesthetized Schirmer's Test (UA ST) score ≥1 and \< 10 mm/5 min and baseline total Corneal Fluorescein Staining (tCFS) score ≥2 and ≤ 15 (National Eye Institute, NEI, grading scale).

Exclusion criteria

Exclusion Criteria:

Subjects with any of the following conditions on the eligibility exam may NOT be enrolled into the trial.

  1. History of ocular surgery within the past 6 months.
  2. Contact lens wear in either eye within 7 days of visit 1 (baseline) or use during study
  3. On current topical treatment regimen for less than 3 months or anticipates any change to the regimen during the study period.
  4. Use of topical ocular medication or varenicline nasal spray within 4 weeks of baseline or during the study period.
  5. Use of artificial tears within 2 hours prior to the baseline or study visit days.
  6. Any known allergies to any component of the study drug.
  7. Severe, uncontrolled disease (e.g., rheumatoid arthritis, lupus). Uncontrolled is at the discretion of the PI. Subjects with severe systemic symptoms will not be included.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Study eye

    The study eye is the eye with the lower pre-drop unanesthetized Schirmer score performed at the baseline visit.

    Drug: TRYPTYR (Acoltremon ophthalmic solution 0.003%)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from pre-instillation to 3 minutes post-TRYPTYR instillation in study eye unanesthetized Schirmer's test at Visit 1 (baseline)

    Unanesthetized Schirmer's test will be measured prior to instillation and then again 3 minutes after instillation of the TRYPTYR. The difference between the 2 measurements will be compared.

    Time frame: 3 minutes

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 11, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07277257
Lead sponsor
Center For Sight
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Dec 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 22, 2025

Study contacts

Gina Thomas
Contact
gina.thomas@useye.com
9412634784

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acoltremon

Start the discussion